Sirtris Pharmaceuticals Added to Russell 3000(R) Index
June 25 2007 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that it was added to the Russell 3000(R) Index as well as the
Russell Microcap(R) Index when Russell Investment Group
reconstituted its family of U.S. indexes on June 22, 2007. �Being
included among the leading growth companies in the U.S. in the
Russell Indexes is an honor. We believe that this achievement is a
reflection of the scientific progress we have made in developing
new therapies to treat diseases of aging," said Christoph Westphal,
M.D., Ph.D., Chief Executive Officer of Sirtris Pharmaceuticals,
Inc. Membership in the Russell 3000(R), which remains in place for
one year, means Sirtris will automatically be included in the
Russell Microcap (R), as well as appropriate growth and value style
indexes. Russell determines membership for its equity indexes
primarily by objective, market-capitalization rankings and style
attributes. According to Russell, Russell indexes are widely used
by investment managers and institutional investors for index funds
and as benchmarks for both passive and active investment
strategies. $4 trillion in assets currently are benchmarked to
Russell indexes, and investment managers who oversee these funds
purchase shares of member stocks according to that company's
weighting in the particular index. About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 concerning Sirtris
Pharmaceuticals, its product candidates, and those candidates'
clinical potential. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the Company's
potential inability to initiate and complete preclinical studies
and clinical trials for its product candidates, the fact that none
of the Company's product candidates has received regulatory
approvals, the potential inability of the�Company to gain market
acceptance of the Company's product candidates, and those other
risks factors�that can be found in the�Company's filings with the
Securities and Exchange Commission. Actual results may differ
materially from those Sirtris Pharmaceuticals contemplated by these
forward-looking statements. Sirtris Pharmaceuticals does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024